Shareholder Alert: Ademi LLP Investigates Whether Akili, Inc. Has Obtained a Fair Price for Its Public Shareholders
Shareholder Alert: Ademi LLP Investigates Whether Akili, Inc. Has Obtained a Fair Price for Its Public Shareholders
MILWAUKEE, May 29, 2024 /PRNewswire/ -- Ademi LLP is investigating Akili (Nasdaq: AKLI) for possible breaches of fiduciary duty and other violations of law in its transaction with Virtual Therapeutics.
密爾沃基,2024年5月29日 /PRNewswire/ — Ademi LLP正在調查Akili(納斯達克股票代碼:AKLI)在與Virtual Therapeutics的交易中可能違反信託義務和其他違法行爲。
Click here to learn how to join the or call Guri Ademi toll-free at 866-264-3995. There is no cost or obligation to you.
點擊此處了解如何加入或撥打 Guri Ademi 的免費電話 866-264-3995。您無需支付任何費用或承擔任何義務。
In the transaction, Akili shareholders will receive only $0.4340 per share of common stock in cash. The transaction agreement unreasonably limits competing transactions for Akili by imposing a significant penalty if Akili accepts a competing bid. Akili insiders will receive substantial benefits as part of change of control arrangements.
在這筆交易中,Akili股東將僅獲得每股普通股0.4340美元的現金。該交易協議不合理地限制了Akili的競爭交易,如果Akili接受競爭性出價,將處以巨額罰款。作爲控制權變更安排的一部分,Akili內部人士將獲得可觀的收益。
We are investigating the conduct of Akili's board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.
我們正在調查Akili董事會的行爲,以及他們是否履行了對所有股東的信託責任。
If you own Akili common stock and wish to obtain additional information, please contact Guri Ademi either at [email protected] or toll-free: 866-264-3995, or
如果你擁有Akili普通股並希望獲得更多信息,請致電 [email protected] 或免費電話:866-264-3995 與 Guri Ademi 聯繫,或
We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights throughout the country. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.
我們專門處理涉及收購、合併和全國各地個人股東權利的股東訴訟。欲了解更多信息,請隨時致電我們。律師廣告。先前的結果並不能保證類似的結果。
Contacts
聯繫人
Ademi LLP
Guri Ademi
Toll Free: (866) 264-3995
Fax: (414) 482-8001
Ademi LLP
Guri Ademi
免費電話:(866) 264-3995
傳真:(414) 482-8001
SOURCE Ademi LLP
來源 Ademi LLP
譯文內容由第三人軟體翻譯。